Lead Product(s) : L-Fucose
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The active pharmaceutical ingredient (API) in AVTX-803 is L-fucose an oral formulation of L-fucose that enhances fucosylation of proteins in the absence of a functioning GDP-fucose transporter, partially restoring protein function.
Brand Name : AVTX-803
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 02, 2022
Lead Product(s) : L-Fucose
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?